Evidence map›Paper›PMID 39936592›Full record

ArticleThe ISME journal2025

Targeted prebiotic application of gluconic acid-containing oligosaccharides promotes Faecalibacterium growth through microbial cross-feeding networks.

Hiroki Negishi, Ayumi Ichikawa, Saori Takahashi, Hiroshi Kano, Seiya Makino

Abstract read
In one paragraph

Article in The ISME journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hiroki NegishiWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo 192-0919, Japan.
Ayumi IchikawaWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo 192-0919, Japan.
Saori TakahashiWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo 192-0919, Japan.
Hiroshi KanoWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo 192-0919, Japan.
Seiya MakinoWellness Science Labs, Meiji Holdings Co., Ltd., Tokyo 192-0919, Japan.

Funding

Meiji Holdings Co., Ltd
6 · The paper itself

Abstract

The gut microbiome plays a crucial role in human health, and certain bacterial species, such as Faecalibacterium prausnitzii, are particularly beneficial. This study conducted a comprehensive investigation of prebiotic compounds that showed potential for specifically promoting beneficial gut bacteria. Using in vitro fecal cultures and a human intervention study, we identified maltobionic acid and lactobionic acid as compounds that specifically promoted Faecalibacterium growth both in vitro and in vivo without significantly affecting Bifidobacterium, which is typically increased by traditional prebiotics. In a human intervention study (n = 27), a significant increase was observed in Faecalibacterium abundance following maltobionic acid supplementation, with effectiveness correlating with the initial Parabacteroides abundance. Mechanistic investigations revealed a cross-feeding pathway between gut bacteria. In this pathway, Parabacteroides species converted the gluconic acid moiety of maltobionic and lactobionic acids to glucuronic acid, which was then preferentially utilized by Faecalibacterium. These findings suggest that gluconic acid-containing oligosaccharides are promising prebiotics for the targeted enhancement of beneficial Faecalibacterium and underscore the importance of microbial interactions in prebiotic research, offering new avenues for personalized microbiome modulation strategies.

Indexed as

FaecalibacteriumGastrointestinal MicrobiomeGluconatesOligosaccharidesPrebioticsAdultDisaccharidesFecesFemaleHumansMaleYoung AdultDisaccharidesGluconatesgluconic acidlactobionic acidOligosaccharidesPrebioticscross-feedingFaecalibacteriumgut microbiotamaltobionic acidParabacteroidesprebiotics

Identifiers

PMID39936592
PMCPMC11922316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.